Slovenian drugmaker Lek, which owns PharmaTech TAâsrgu-Mures, last year recorded sales worth 24m euros on the Romanian market, up 21% since 2001. Consequently, the company’s market share increased from 3.5% to 3.9%. However, Lek also found it difficult to get its money from the hospitals. Lek is a medium-size company in Europe, but holds a strong position on the Central and Eastern European market. The Slovenian drugmaker bought Romanian player PharmaTech TAâsrgu-Mures at the end of 2002 for $9.5 million. ZF
ZF English
Lek grows 21%
Slovenian drugmaker Lek, which owns PharmaTech TAâsrgu-Mures, last year recorded sales worth 24m euros on the Romanian market, up 21% since 2001. Consequently, the company's market share increased from 3.5% to 3.9%. However, Lek also found it difficult to get its money from the hospitals